Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 125

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 125
---
 to 18 U.S.C Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002x   97Incentive-Based Compensation Recovery Policy 10-K9703/28/24101.INSXBRL Instance Documentx   101.SCHXBRL Taxonomy Schemax   101.CALXBRL Taxonomy Extension Calculation Linkbasex   101.DEFXBRL Taxonomy Extension Definition Linkbasex   101.LABXBRL Taxonomy Extension Label Linkbasex   101.PREXBRL Taxonomy Extension Presentation Linkbasex   

________________ 

* Indicates management compensatory plan, contract or arrangement.

Item 16. Form 10-K Summary

None.

 67Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 ENDRA Life Sciences Inc.     Dated: March 31, 2025By:/s/ Alexander Tokman   Alexander Tokman   Chief Executive Officer and Chairman of the Board of Directors(Principal Executive Officer) 

POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of ENDRA Life Sciences Inc., hereby severally constitute and appoint each of Alexander Tokman and Richard Jacroux our true and lawful attorney, with full power to him to sign for us and in our names in the capacities indicated below, any amendments to this Annual Report on Form 10-K, and generally to do all things in our names and on our behalf in such capacities to enable ENDRA Life Sciences Inc. to comply with the provisions of the Securities Exchange Act of 1934, as amended, and all the requirements of the Securities Exchange Commission.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signatures Title Date     /s/ Alexander Tokman Acting Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer) March 31, 2025Alexander Tokman         /s/ Richard Jacroux Chief Financial Officer (Principal Financial and Accounting Officer) March 31, 2025Richard Jacroux